PUBLIC COMPANY
save$RGNXREGENXBIO Inc.
$RGNXRockville, MD, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Long Term Follow-up for RGX-202
- phase2RGX-111 Gene Therapy in Patients With MPS I
- phase3RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
- phase3AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
- —AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
- phase3CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
- phase2RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)
- —Long Term Follow-Up for RGX-111
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 10, 26SELLPAKOLA STEVE· Chief Medical Officer−$53K↗
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that